ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

RGEDF Chemical Works of Richter Gedeon PLC (PK)

24.905
0.00 (0.00%)
01 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Chemical Works of Richter Gedeon PLC (PK) USOTC:RGEDF OTCMarkets Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 24.905 16.49 29.70 0.00 21:18:26

Hungary Richter, US Forest Announce Positive Drug Tests

29/10/2009 8:47am

Dow Jones News


Chemical Works of Richte... (PK) (USOTC:RGEDF)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more Chemical Works of Richte... (PK) Charts.

Hungarian drug maker Richter Gedeon Nyrt. (RICHTER.BU) and Forest Laboratories Inc. (FRX) announced positive drug test results on cariprazine Thursday in a stock exchange filing.

"The results strengthen our commitment to conduct original research in the field of central nervous system disorders, where our team has excellent expertise," the release cited Erik Bogsch, chief executive of Richter as saying.

Based on the data - still subject to a complete review of the full results - and the previously announced Phase II results in patients suffering from acute mania associated with bipolar I disorder, the companies intend to initiate Phase 3 trials for both indications in early 2010. "Our strategy to invest in promising product opportunities ... continues to bear fruit and we are looking forward to advancing to the late-stage cariprazine development program," the release cited Howard Solomon, Chairman and Chief Executive of Forest Laboratories as saying.

The companies announced top-line results from a Phase IIb clinical trial of the novel, investigational antipsychotic agent cariprazine for the treatment of acute exacerbation of schizophrenia.

PANSS, or Positive and Negative Syndrome Scale, data indicated that patients with schizophrenia treated with cariprazine experienced significant symptom improvement compared to placebo patients within the first week of treatment and at each subsequent time point studied.

Cariprazine is currently also undergoing Phase II clinical trials in patients with Bipolar Depressive Disorder and as adjunctive therapy in Major Depressive Disorder.

Discovered by researchers at Richter and licensed in the United States and Canada by Forest Laboratories in 2004, cariprazine is an orally active D3/D2 partial agonist with preferential binding to D3 receptors.

Richter Web site: www.richter.hu

 
 
 
 

1 Year Chemical Works of Richte... (PK) Chart

1 Year Chemical Works of Richte... (PK) Chart

1 Month Chemical Works of Richte... (PK) Chart

1 Month Chemical Works of Richte... (PK) Chart

Your Recent History

Delayed Upgrade Clock